Lack of Effect of Methylphenidate on Serum Growth Hormone (GH), GH-Binding Protein, and Insulin-like Growth Factor I

Toren, Paz; Silbergeld, A.; Eldar, Sofia; Laor, Nathaniel; Wolmer, Leo; Koren, Sharon; Weitz, Raphael; Inbar, Dov; Reiss, Ahuva; Eshet, R; Weizman, Ronit

doi:10.1097/00002826-199706000-00011

Cited by 19 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bereket et al showed that MP caused a transient decrease in IGF-I and IGFBP-3 levels [19]. On the other hand a study by Toren et al found no difference in GH, GH binding protein and IGF-I levels [40]. Our results suggest that the cause of growth deceleration does not seem to be the result of significantly lower IGF-I and IGFBP-3 levels.…”

Section: Discussioncontrasting

confidence: 39%

Methylphenidate and the Response to Growth Hormone Treatment in Short Children Born Small for Gestational Age

et al. 2012

View full text Add to dashboard Cite

BackgroundGrowth hormone (GH) treatment has become a frequently applied growth promoting therapy in short children born small for gestational age (SGA). Children born SGA have a higher risk of developing attention deficit hyperactivity disorder (ADHD). Treatment of ADHD with methylphenidate (MP) has greatly increased in recent years, therefore more children are being treated with GH and MP simultaneously. Some studies have found an association between MP treatment and growth deceleration, but data are contradictory.ObjectiveTo explore the effects of MP treatment on growth in GH-treated short SGA childrenMethodsAnthropometric measurements were performed in 78 GH-treated short SGA children (mean age 10.6 yr), 39 of whom were also treated with MP (SGA-GH/MP). The SGA-GH/MP group was compared to 39 SGA-GH treated subjects. They were matched for sex, age and height at start of GH, height SDS at start of MP treatment and target height SDS. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) levels were yearly determined. Growth, serum IGF-I and IGFBP-3 levels during the first three years of treatment were analyzed using repeated measures regression analysis.ResultsThe SGA-GH/MP group had a lower height gain during the first 3 years than the SGA-GH subjects, only significant between 6 and 12 months of MP treatment. After 3 years of MP treatment, the height gain was 0.2 SDS (±0.1 SD) lower in the SGA-GH/MP group (P = 0.17). Adult height was not significantly different between the SGA-GH/MP and SGA-GH group (−1.9 SDS and −1.9 SDS respectively, P = 0.46). Moreover, during the first 3 years of MP treatment IGF-I and IGFBP-3 measurements were similar in both groups.ConclusionMP has some negative effect on growth during the first years in short SGA children treated with GH, but adult height is not affected.

show abstract

Section: Discussioncontrasting

confidence: 39%

Methylphenidate and the Response to Growth Hormone Treatment in Short Children Born Small for Gestational Age

et al. 2012

View full text Add to dashboard Cite

show abstract

“…On the other hand, an in vitro study showed that methylphenidate and other psychostimulants inhibited IGF bioactivity in cartilage tissue [33]. A cross-sectional study undertaken in 6- to 16-year-old (mixed prepubertal and pubertal) children with ADHD found no difference in GH, GHBP and IGF-I levels between a methylphenidate-treated group and control group [34]. We have found that serum IGF-I and IGFBP-3 concentrations are within normal limits for age and sex in children with ADHD before treatment.…”

Section: Discussionmentioning

confidence: 99%

Height, Weight, IGF-I, IGFBP-3 and Thyroid Functions in Prepubertal Children with Attention Deficit Hyperactivity Disorder: Effect of Methylphenidate Treatment

Bereket¹,

Turan²,

Karaman³

et al. 2005

Horm Res Paediatr

View full text Add to dashboard Cite

Objective: To investigate if there are any disease-related or methylphenidate-induced aberrations in growth parameters, growth hormone insulin-like growth factor (IGF)-I, IGFBP-3 axis and the thyroid function tests in children with attention deficit hyperactivity disorder (ADHD). Methods: Newly diagnosed and untreated prepubertal children with ADHD were longitudinally followed before and approximately every 4 months after methylphenidate treatment for up to 16 months. Height SDS, weight SDS, BMI SDS, serum GH, IGF-I, IGFBP-3, T₄, free T₄, T₃, and TSH were measured at each visit. Results: All of the examined parameters were within normal limits for age before treatment. Methylphenidate treatment did not significantly affect SDS of height, weight, BMI, IGF-I and IGFBP-3 in the long run. Serum T₄ and free T₄ levels showed modest reductions within normal limits in a time-dependent manner. Conclusions: Prepubertal children with ADHD had normal height, weight, BMI, serum IGF-I and IGFBP-3 and thyroid functions. Methylphenidate treatment had no sustained effects on growth parameters, IGF-I and IGFBP-3 during the follow-up period of this study. However, it caused a mild decrease in total and free T₄ which may warrant further monitoring.

show abstract

“…Indeed, a handful of older studies [42][43][44] have reported an increase in human GH levels with methylphenidate usage. Furthermore, Bereket et al [2] reported methylphenidate to be associated with mild, but transient decreases in serum IGF-1 and IGF binding protein 3 (IGFBP-3) levels, while Toren et al [45] found that boys with ADHD treated with methylphenidate do not differ from untreated boys, or from control subjects, with regards to fasting serum GH, GH binding protein (GHBP) or IGF-1 levels. More than the absolute serum levels are necessary to be able to assess the influence of these stimulants on growth hormone functioning and, as yet, not much has been done in this respect.…”

Section: Stimulants and Growth Hormonementioning

confidence: 99%

“…The majority of studies have found that dopamine causes a decrease in GH concentrations [44][45][46][47][48]52]. In animals, dopamine has been found to decrease the secretion of GH by pituitary cells due to an increase in the release of somatostatin [57][58][59].…”

Section: Stimulants and Growth Hormonementioning

confidence: 99%

Stimulants and growth in children with attention-deficit/hyperactivity disorder

Negrao

Viljoen

2011

Medical Hypotheses

View full text Add to dashboard Cite

a b s t r a c tInitial suggestions that suppression of growth may be an intrinsic characteristic of attention-deficit/ hyperactivity disorder (ADHD) have now largely been disproven. Although controversy persists regarding the possible negative effect of adrenergic stimulants on growth in children with ADHD, the consensus that appears to be reached in the scientific literature is that stimulant usage may cause a manageable attenuation of growth in these children. Since it is known that stimulants increase the amount of dopamine and noradrenaline in the synapse, this writing suggests that these increases in dopamine and noradrenaline are responsible for the growth attenuation in these children. It appears that increased amounts of dopamine and noradrenaline have the ability to inhibit the secretion of growth hormone and growth-related hormones such as prolactin, thyroid hormones, sex hormones and insulin. Therefore, it would be reasonable to suggest that the increases in dopamine and noradrenaline caused by stimulant usage can disrupt the homeostasis of both growth hormone and growth-related hormones, generating the potential for the suppression of growth.

show abstract

Lack of Effect of Methylphenidate on Serum Growth Hormone (GH), GH-Binding Protein, and Insulin-like Growth Factor I

Cited by 19 publications

References 0 publications

Methylphenidate and the Response to Growth Hormone Treatment in Short Children Born Small for Gestational Age

Methylphenidate and the Response to Growth Hormone Treatment in Short Children Born Small for Gestational Age

Height, Weight, IGF-I, IGFBP-3 and Thyroid Functions in Prepubertal Children with Attention Deficit Hyperactivity Disorder: Effect of Methylphenidate Treatment

Stimulants and growth in children with attention-deficit/hyperactivity disorder

Contact Info

Product

Resources

About